S5 Ep44: Monk Talks Tisotumab Vedotin and Exciting ESMO Data in Cervical Cancer

OncLive® On Air - En podkast av OncLive® On Air

Prøv Podimo gratis i hele 60! dager!

I Podimo finner du eksklusive podkaster og bestselgende lydbøker tilpasset dine ører

Dr. Monk discusses the significance of the FDA approval of tisotumab vedotin and notable research that was presented at the 2021 ESMO Congress in cervical cancer.

Visit the podcast's native language site